Monitoring blood glucose levels may help manage this
Being male (paradoxically, except for androgenetic alopecia), starting at lower retatrutide doses with slow titration, maintaining excellent nutrition throughout, having no history of stress-related shedding, and having robust baseline micronutrient levels all lower your likelihood of significant hair loss
Phase 2 trial (NEJM, 2023) The landmark Phase 2 trial, published in the New England Journal of Medicine, randomized 338 adults with obesity to receive weekly subcutaneous retatrutide at doses of 1 mg, 4 mg, 8 mg, or 12 mg, or placebo, for 48 weeks
Clinical evidence head to head Tirzepatide: SURMOUNT-1 (Jastreboff et al., NEJM 2022) showed mean weight reduction of 20.9% at 15 mg weekly across 72 weeks
However, if you have a sensitive stomach, taking it with a light meal is also an option
May 23 2022;12(3):281-289